Oncotarget

Reviews:

CD248: A therapeutic target in cancer and fibrotic diseases

Beverly A. Teicher _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:993-1009. https://doi.org/10.18632/oncotarget.26590

Metrics: PDF 314 views  |   HTML 432 views  |   ?  


Abstract

Beverly A. Teicher1

1Molecular Pharmacology Branch, Developmental Therapeutics Program, DCTD, National Cancer Institute, Bethesda 20892, MD, USA

Correspondence to:

Beverly A. Teicher, email: Beverly.Teicher@nih.gov teicherba@mail.nih.gov

Keywords: CD248; endosialin; TEM1; sarcoma; fibrotic disease

Received: November 29, 2018     Accepted: December 22, 2018     Published: January 29, 2019

ABSTRACT

CD248/endosialin/TEM1 is a type 1 transmembrane glycoprotein found on the plasma membrane of activated mesenchymal cells. CD248 functions during embryo development and is either not expressed or found at very low levels in adult tissues. CD248 is expressed at high levels by malignant sarcoma cells, by the pericyte component of tumor vasculature and by mesenchymal cells in some fibrotic diseases. CD248 is being targeted by several experimental therapeutics including antibodies, antibody drug conjugates, as an antigen for CART cells and in therapeutic vaccines. Although the function of CD248 has yet to be fully elucidated, this protein is a potential broad scope therapeutic target.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26590